
1-phenoxazin-10-ylethanone
CAS No. 6192-43-4
1-phenoxazin-10-ylethanone ( 10-acetylphenoxazine | N-Acetylphenoxazine | HJ-PI01 )
产品货号. M28779 CAS No. 6192-43-4
1-phenoxazin-10-ylethanone 是一种 Pim-2 抑制剂。 1-phenoxazin-10-ylethanone 诱导三阴性人类乳腺癌细胞凋亡和自噬性细胞死亡。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥988 | 有现货 |
![]() ![]() |
10MG | ¥1596 | 有现货 |
![]() ![]() |
25MG | ¥3686 | 有现货 |
![]() ![]() |
50MG | ¥5443 | 有现货 |
![]() ![]() |
100MG | ¥7744 | 有现货 |
![]() ![]() |
500MG | ¥15552 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称1-phenoxazin-10-ylethanone
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述1-phenoxazin-10-ylethanone 是一种 Pim-2 抑制剂。 1-phenoxazin-10-ylethanone 诱导三阴性人类乳腺癌细胞凋亡和自噬性细胞死亡。
-
产品描述1-phenoxazin-10-ylethanone is a Pim-2 inhibitor. 1-phenoxazin-10-ylethanone induces apoptosis and autophagic cell death in triple-negative human breast cancer.
-
体外实验Western Blot Analysis Cell Line:MDA-MB-231 cell line Concentration:300 and 460 nmol/L Incubation Time:12, 24, 36 and 48 hours Result:Time-dependently increased LC3-II and Beclin-1 and induced p62 degradation in MDA-MB-231 cells. Increased the level of Bax. Decreased the level of Bcl-2, and Pim-2 and Pim-2 phosphorylation. Activated caspase-9 and caspase-3.
-
体内实验Animal Model:BALB/c female nude mice with MDA-MB-231 cells injection Dosage:40 mg/kg Administration:Oral administration; 40 mg/kg, once daily for 10 days Result:Significantly inhibited tumor growth with an obvious decreasing of the body, liver, spleen and kidney weights of the mice.
-
同义词10-acetylphenoxazine | N-Acetylphenoxazine | HJ-PI01
-
通路JAK/STAT Signaling
-
靶点Pim
-
受体histone acetyltransferase
-
研究领域——
-
适应症——
化学信息
-
CAS Number6192-43-4
-
分子量225.247
-
分子式C14H11NO2
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 50 mg/mL (221.99 mM)
-
SMILESCC(=O)N1c2ccccc2Oc2ccccc12
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Klotilda Narkaj, et al. Blocking H2A.Z Incorporation via Tip60 Inhibition Promotes Systems Consolidation of Fear Memory in Mice. eNeuro. 2018 Nov 8;5(5):ENEURO.0378-18.2018.